Ghent University Academic Bibliography

Your filters: cql: author="Van Pesch, Vincent" or (type any "bookEditor issueEditor" and editor="Van Pesch, Vincent")

Add to list
- Journal Article
- A1
- open access
Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis : an MSBase registry sub-study

Helmut Butzkueven, Pamela Farr, Serkan Ozakbas, Cavit Boz, Tomas Kalincik, Lisa Taylor, Anneke Van Der Walt, Raed Alroughani, Katherine Buzzard, Olga Skibina, et al.

(2026) MULTIPLE SCLEROSIS AND RELATED DISORDERS. 106.
Add to list
Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

Yi Chao Foong, Daniel Merlo, Melissa Gresle, Katherine Buzzard, Dana Horakova, Eva Kubala Havrdova, Tomas Kalincik, Izanne Roos, Suzanne Hodgkinson, Jeannette Lechner-Scott, et al.

(2026) JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 97(1). p.50-58
Add to list
- Journal Article
- A1
- open access
Cognitive functioning in multiple sclerosis with focus on brainstem volume

Eline Van Doninck, Anna-Victoria De Keersmaecker, Marie D’hooghe, Bart Van Wijmeersch, Gaetano Perrotta, Souraya El Sankari, Vincent van Pesch, Dominique Dive, Miguel D’Haeseleer, Guy Laureys (UGent) , et al.

(2025) ACTA NEUROLOGICA BELGICA.
Add to list
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years

Jodie I Roberts, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Serkan Ozakbas, Alessandra Lugaresi, Valentina Tomassini, Raed Alroughani, Katherine Buzzard, Olga Skibina, et al.

(2025) JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 96(12). p.1185-1193
Add to list
Explainable time-to-progression predictions in multiple sclerosis

Robbe D’hondt, Klest Dedja, Sofie Aerts, Bart Van Wijmeersch, Tomas Kalincik, Stephen Reddel, Eva Kubala Havrdova, Alessandra Lugaresi, Bianca Weinstock-Guttman, Saloua Mrabet, et al.

(2025) COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE. 263.
Add to list
- Journal Article
- A2
- open access
Persistent progression independent of relapse activity in multiple sclerosis

Chao Zhu, Zhen Zhou, Tomas Kalincik, Izanne Roos, Katherine Buzzard, Olga Skibina, Raed Alroughani, Jens Kuhle, Marc Girard, Pierre Grammond, et al.

(2025) BRAIN COMMUNICATIONS. 7(5).
Add to list
- Journal Article
- A1
- open access
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Simona Toscano, Tim Spelman, Serkan Ozakbas, Raed Alroughani, Clara G. Chisari, Salvatore Lo Fermo, Alexandre Prat, Marc Girard, Pierre Duquette, Guillermo Izquierdo, et al.

(2025) NEUROTHERAPEUTICS. 22(2).
Add to list
- Journal Article
- A1
- open access
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

Ashkan Pirmani, Edward De Brouwer, Ádám Arany, Martijn Oldenhof, Antoine Passemiers, Axel Faes, Tomas Kalincik, Serkan Ozakbas, Riadh Gouider, Barbara Willekens, et al.

(2025) NPJ DIGITAL MEDICINE. 8(1).
Add to list
Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis

Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Dana Horakova, Bianca Weinstock-Guttman, Vahid Shaygannejad, Masoud Etemadifar, Raed Alroughani, et al.

(2025) JAMA NEUROLOGY. 82(6). p.614-625
Add to list
- Journal Article
- A1
- open access
Four years on : pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, Sara Eichau, Stella Hughes, Barbara Willekens, Dana Horakova, Eva Kubala Havrdova, Serkan Ozakbas, Cavit Boz, et al.

(2025) MULTIPLE SCLEROSIS JOURNAL. 31(9). p.1088-1101

Academic Bibliography

Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis : an MSBase registry sub-study

Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

Cognitive functioning in multiple sclerosis with focus on brainstem volume

Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years

Explainable time-to-progression predictions in multiple sclerosis

Persistent progression independent of relapse activity in multiple sclerosis

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis

Four years on : pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

Contents

Support

Contact